מנבאו

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

MENINGOCOCCAL VACCINES GROUP A; MENINGOCOCCAL VACCINES GROUP C; MENINGOCOCCAL VACCINES GROUP W; MENINGOCOCCAL VACCINES GROUP Y

Commercializzato da:

GLAXO SMITH KLINE (ISRAEL) LTD

Codice ATC:

J07AH02

Forma farmaceutica:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Composizione:

MENINGOCOCCAL VACCINES GROUP Y 5 MCG / 0.5 ML; MENINGOCOCCAL VACCINES GROUP W 5 MCG / 0.5 ML; MENINGOCOCCAL VACCINES GROUP C 5 MCG / 0.5 ML; MENINGOCOCCAL VACCINES GROUP A 10 MCG / 0.5 ML

Via di somministrazione:

תוך-שרירי

Tipo di ricetta:

מרשם נדרש

Prodotto da:

GLAXO SMITHKLINE VACCINES S.R.L., ITALY

Gruppo terapeutico:

OTHER MENINGOCOCCAL MONOVALENT PURIFIED POLYSACCHARIDES ANTIGEN

Area terapeutica:

OTHER MENINGOCOCCAL MONOVALENT PURIFIED POLYSACCHARIDES ANTIGEN

Indicazioni terapeutiche:

Menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.

Dettagli prodotto:

החיסון יינתן עבור חולה הלוקה באחד מאלה:1. אספלניה, היפוספלניה אנטומית או תפקודית, נרכשת או מולדת.2. חסר במערכת המשלים כגון חסר בפקטור D, פרופרידין ובמרכיב המשלים C5-9 או C3

Data dell'autorizzazione:

2017-08-31